# OnCo record hemogenyx-pharmaceuticals (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/hemogenyx-pharmaceuticals/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "hemogenyx-pharmaceuticals" ;
  schema:name "Hemogenyx Pharmaceuticals"@en ;
  schema:alternateName "Hemogenyx Pharmaceuticals plc"@en ;
  schema:description "Hemogenyx Pharmaceuticals is developing a CAR-T cell therapy, a patient's own immune cells engineered to attack cancer, aimed at the FLT3 protein on acute myeloid leukaemia cells. It is in a first trial at MD Anderson for leukaemia that has come back or stopped responding."@en ;
  schema:url <https://onco.cc/companies/hemogenyx-pharmaceuticals/>, <https://hemogenyx.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://hemogenyx.com/>, <https://hemogenyx.com/pipeline/>, <https://clinicaltrials.gov/study/NCT06786533> ;
  schema:addressCountry "GB" ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/flt3/>, <https://onco.cc/targets/cd3/> .